Phillip Lam, MD

@PhilLamMD

Advanced Heart Failure and Transplant Cardiologist @MedstarWHC; APD @GTCardFellows; Associate Professor of Medicine @GUMedicine; Alum @UVMLarnerMed @Cornell

Washington, DC Joined April 2018

394 Following 715 Followers 524 Posts

Latest posts 5

Phillip Lam, MD @PhilLamMD Apr 27

Initiation of NB therapy during index HM3 LVAD implant associated with improved survival, a finding that needs to be prospectively studied @FlaviaTejadaF @fsheikh22 @RichaGuptaMD @MedStarHealth @GTCardFellows @IMMWHC onlinelibrary.wiley.com/doi/abs/10.111…

onlinelibrary.wiley.com Initiation of Neurohormonal Blockade and Clinical Outcomes in HeartMate 3 LVAD Recipients During... Early neurohormonal blockade (NB) therapy at index discharge after HeartMate 3 (HM3) left ventricular assist device (LVAD) implantation was associated with lower age-sex-race-adjusted all-cause...

Phillip Lam, MD @PhilLamMD Apr 25

HF phenotyping using AI approaches demonstrating comparable clinical outcomes to traditional ICD coding, suggesting potential utility of AI to improve care, operations, and research @aamdmph @gcfmd @JCardFail @GTCardFellows @fsheikh22 @MedStarHealth @DCVAMC

Gregg Fonarow MD @gcfmd Apr 25

Characteristics and Outcomes of Over One Million Veterans with Heart Failure Phenotyped Using Artificial Intelligence Approaches: The National DCVA-HF Registry - Journal of Cardiac Failure onlinejcf.com/article/S1071-…

@aamdmph @boback @ATSandhu @JCardFail
View quoted post on X

Phillip Lam, MD @PhilLamMD Mar 24

Looking forward to attending the #ACC26 PDGME recommended sessions including the symposium on 3/27! @ACCinTouch @docbfreed @gabyweissman @ckaiseroll @MarkHofmeyer @MedStarHealth @GTCardFellows

Phillip Lam, MD @PhilLamMD Mar 20

Early career professionals, come check out our financial literacy 101 session at #ACC26! Important topics to be covered! #accpdgme @Stanley_Liu_MD @DrToniyaSingh @ACCinTouch @SelmaFMohammed @GTCardFellows @RichaGuptaMD @fsheikh22 @WaqasHaiderMD @acc

Phillip Lam, MD @PhilLamMD Mar 11

Findings from our study demonstrate that in patients with HFrEF, target dose ACEIs were associated with lower risk of kidney failure and death academic.oup.com/eurjhf/advance… @gcfmd @DCVAMC @MedStarHealth

academic.oup.com Target-dose vs below-target-dose ACE inhibitors and lower risk of kidney failure and mortality in... AbstractAims. In randomized controlled trials, target-dose angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) improv